-
well as disease relapse in order to design novel inhibitors to intervene the malignancies; 3) collaborative analyses of myeloid cancers genomics using high-throughput single-cell technology. The group conducts
-
transduction, ELISA, CART production, CRISPR/Cas9 technology · In vivo skills: o Routes of drug administration: oral gavage, intraperitoneal, retro-orbital, subcutaneous, or tail vein injections o
-
, shaping the future of medicine through cutting-edge research. The Department of Integrative Translational Sciences at City of Hope comprises a diverse team of biologists, data scientists, engineers
-
, including first-in-human studies with genetically engineered hematopoietic stem and progenitor cells (HSPC) and T cells. As a successful candidate, you will: · Conduct research on next-generation
-
. Human synthetic insulin, monoclonal antibodies and numerous breakthrough cancer drugs are based on technology developed at the institution. AccessHope™, a subsidiary launched in 2019 serves employers and
-
leukemogenesis as well as disease relapse in order to design novel inhibitors to intervene the malignancies · Collaborative analyses of myeloid cancers genomics using high-throughput single-cell technology
-
and identification of HLA-restricted epitopes derived from them As a successful candidate, you will: · Work with both genetically engineered mouse models, patient-derived AML xenograft models
-
. For more information on Dr. Schones’ research please visit here . · PhD or M.D. in biology, computer science, biomedical engineering, physics or other related discipline. · Excellent
-
. Human synthetic insulin, monoclonal antibodies and numerous breakthrough cancer drugs are based on technology developed at the institution. AccessHope™, a subsidiary launched in 2019 serves employers and
-
labs involved in cutting edge technology, research, and clinical immunotherapeutic programs. Dr. Lior Goldberg’s lab currently has an opening for a Postdoctoral Fellow who will develop chimeric antigen